Project Grant R01MH137472

Award Date 7/3/24
Completion Date 2/28/29
Dollars Obligated $1.9M
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Boulder, CO 80309, USA
Similar Awards
This Project Grant award, provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), will support research to determine the physiological and behavioral role of ventral tegmental area (VTA) neurons that co-release the neurotransmitters GABA and glutamate in the amygdala. The $248,998 grant will fund experiments by the Principal Investigator, who is moving to a tenure-track position at Dartmouth College, to monitor the activity of...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $613,017 to the University of California, Los Angeles (UCLA) to conduct research on the dopaminergic mechanisms underlying reinforcement learning and timing. The central objectives of the 5-year project are to: Examine how the temporal precision of dopamine reward omission signals and striatal dynamics change across learning in a classical trace...
This Project Grant award, valued at $629,844.00, was issued by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award will support research at Duke University to elucidate the function of the ventral tegmental area (VTA) circuits and their contribution to the learning and performance of motivated behaviors. The research will use bidirectional optogenetics, in vivo electrophysiology and photometry, and quantitative behavioral...
The National Institute on Drug Abuse (NIDA) awarded a $818,513 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Regents of the University of Minnesota to investigate the role of dopamine signaling in the basolateral amygdala in regulating individual differences in reward-based learning strategies and addiction-like behaviors. The 5-year grant, which commenced on Sep 15, 2024, will focus on examining how individual differences in Pavlovian reward learning approaches...
This Project Grant award of $781,032 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research to understand the interplay between norepinephrine and dopamine circuits in the brain and their role in sex differences related to reward and aversion, including substance use disorders. Specifically, the research aims to map the anatomical and neurochemical distribution of norepinephrine projections from...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $148,568 to investigate the mechanisms of dopamine transmission and its role in reward-related behaviors. The award period runs from January 1, 2025 to July 31, 2027. The funded research aims to advance the mechanistic understanding of how dopamine signaling occurs at the subcellular level, given limitations in prior methodologies. The...
This two-year, $140,108 project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will fund research into the co-regulation of striatal dopamine and acetylcholine in associative reward learning. The grantee, The Trustees of Columbia University in the City of New York, will investigate how these two neuromodulators interact to drive associative reward learning processes. Specifically, the researchers will test the hypothesis that striatal...
The University of Washington was awarded a $149,284 Project Grant by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of specific subpopulations of prefrontal cortex pyramidal neurons in regulating drug-seeking behavior. The research aims to elucidate the factors that predispose individuals to addiction and confer vulnerability to relapse, with the goal of advancing understanding of the functional roles of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,351,034 to the University of Alabama at Birmingham (UAB) to research the mechanisms by which somatostatin-expressing interneurons (SST-INs) in the prelimbic region of the prefrontal cortex regulate natural and drug reward seeking behaviors. The 5-year project aims to: 1) reveal the in vivo dynamics, behavioral contributions, and...
This Project Grant award, with a total funding amount of $154,091, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research at Georgetown University to investigate the role of chloride homeostasis and inhibitory network activity in the ventral tegmental area of the brain during reward learning. Specifically, the project aims to characterize the expression of the anion transporter KCC2 and its...

UNTANGLING DOPAMINE AND GLUTAMATE NEURON FUNCTION IN THE VTA - PROJECT SUMMARY / ABSTRACT VENTRAL TEGMENTAL AREA (VTA) DOPAMINE NEURONS ARE ESSENTIAL FOR ASSOCIATIVE LEARNING OF REWARD AND AVERSION- RELATED CUES, UPDATING LEARNED ASSOCIATIONS BY PREDICTION ERRORS, AS WELL AS SUPPORTING A VALUE OF REWARDING AND AVERSIVE OUTCOMES. WHILE IT IS WELL ESTABLISHED THAT VTA DOPAMINE NEURONS SHOW HETEROGENOUS SIGNALING PATTERNS RELATED TO THESE MOTIVATIONALLY-RELEVANT EVENTS, AS WELL AS EXPRESS DIVERSE MOLECULAR CHARACTERISTICS, OUR UNDERSTANDING OF HOW DOPAMINERGIC MOLECULAR HETEROGENEITY CONTRIBUTES TO VTA DOPAMINE NEURON FUNCTIONS ARE UNCLEAR. A PRIMARY DISTINCTION BETWEEN SUBTYPES OF VTA DOPAMINE NEURONS IS WHETHER THEY RELEASE DOPAMINE ALONE OR CO-RELEASE DOPAMINE WITH GLUTAMATE. WE PROPOSE TO TEST THE HYPOTHESIS THAT VTA DOPAMINE NEURON SIGNALING PATTERNS AND ROLES IN MOTIVATED BEHAVIOR ARE GENETICALLY-DETERMINED BY WHETHER THEY CO-RELEASE DOPAMINE WITH GLUTAMATE OR THEY RELEASE DOPAMINE WITHOUT GLUTAMATE. IN AIM 1, WE WILL DETERMINE THE NEURONAL ACTIVITY SIGNALING PATTERNS OF VTA GLUTAMATE-DOPAMINE CO-RELEASING NEURONS, NONGLUTAMATE-DOPAMINE NEURONS, OR GLUTAMATE-ONLY NEURONS THAT DO NOT CO-RELEASE GABA OR DOPAMINE, IN A VARIETY OF REWARD AND AVERSION-BASED MOTIVATED BEHAVIOR TASKS INVOLVING ASSOCIATIVE LEARNING, OUTCOME PREDICTION AND ERRORS, AND OUTCOME VALUES. IN AIM 2, WE WILL CAUSALLY DETERMINE THE ROLES OF THESE SAME NEURONS IN REWARD AND AVERSION-BASED MOTIVATED BEHAVIOR TASKS INVOLVING ASSOCIATIVE LEARNING, OUTCOME PREDICTION, REWARD, AND AVERSION. FINALLY IN AIM 3, WE WILL CAUSALLY DETERMINE THE ROLES OF DOPAMINE AND/OR GLUTAMATE RELEASE FROM THESE DISTINCT VTA NEURONAL PHENOTYPES IN REWARD AND AVERSION-BASED TASKS INVOLVING ASSOCIATIVE AND NONASSOCIATIVE LEARNING AS WELL AS OTHER MOTIVATIONALLY-RELEVANT BEHAVIORS. TOGETHER THESE STUDIES WILL COMPREHENSIVELY IDENTIFY HOW THE MOLECULAR HETEROGENEITY OF THE MIDBRAIN DOPAMINE SYSTEM CONTRIBUTES TO ASSOCIATIVE LEARNING AND MOTIVATED BEHAVIORS.

Posted 7/3/24, 12:00 AM